SCHEDULE 13G/A: Ingalls & Snyder Discloses 7.8% Passive Stake in Corcept Therapeutics

Investment firm Ingalls & Snyder LLC has disclosed a passive beneficial ownership of 7.8% of Corcept Therapeutics Inc.'s common stock as of December 31, 2024.

Summary

• Ingalls & Snyder LLC, a New York-based registered broker-dealer and investment adviser, reported beneficial ownership of 8,173,721 shares of Corcept Therapeutics Inc. common stock.
• This ownership represents 7.8% of Corcept Therapeutics' total outstanding common stock.
• The shares are held with shared dispositive power, meaning Ingalls & Snyder LLC can direct the sale of these securities.
• This filing is an Amendment No. 16 to a Schedule 13G, indicating an update to their previously reported ownership position.
• Ingalls & Snyder LLC certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Corcept Therapeutics Inc.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a passive ownership stake by an institutional investor, which is generally a neutral to slightly positive signal as it indicates confidence from a significant investor. It contains no negative news about the issuer.

Positives

• A notable investment firm, Ingalls & Snyder LLC, holds a substantial 7.8% passive stake in Corcept Therapeutics, which may be interpreted as a vote of confidence in the company's long-term prospects from a significant institutional investor.

Risks

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing control of Corcept Therapeutics, which is a standard regulatory compliance statement for passive investors.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance from Corcept Therapeutics Inc. or Ingalls & Snyder LLC regarding the issuer's future performance.

Industry Context

This filing reflects a significant passive investment by a financial institution in Corcept Therapeutics, a pharmaceutical company. Such disclosures are common in the investment industry, indicating an institutional investor's belief in the long-term value of a company within the healthcare or biotechnology sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by a reputable investment firm like Ingalls & Snyder LLC may be viewed positively, potentially increasing investor confidence and demand for Corcept Therapeutics' stock.

Next Steps

• Ingalls & Snyder LLC will file future amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., by more than 1% or falls below 5%).

Key Dates

Keywords

Corcept Therapeutics, Ingalls & Snyder, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceutical, Biotechnology, Passive Investment